Mar. 2 at 12:02 PM
$KALV KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY (sebetralstat)
https://www.businesswire.com/news/home/20260302212685/en/KalVista-Pharmaceuticals-Presents-New-Data-Highlighting-High-Patient-Satisfaction-and-Evolving-Treatment-Trends-with-EKTERLY-sebetralstat
“The data presented at AAAAI and WSAAI reinforce the importance of treating HAE attacks early, which is consistently associated with improved outcomes,” said Ben Palleiko, CEO of KalVista. “In the KONFIDENT-S open-label extension, we are observing sustained effectiveness and high patient satisfaction with repeated use of sebetralstat, along with meaningful changes in treatment behavior, including treating the majority of attacks, early intervention, and preference for an oral option. Together, these findings support our belief that EKTERLY has the potential to transform how HAE is managed and deliver sustained real-world benefit for people living with HAE.”
